Bjorn Wettermark
Overview
Explore the profile of Bjorn Wettermark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
3380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fors A, Forslund T, Sundstrom A, Wettermark B
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40074942
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained considerable media attention, but there is limited knowledge about those receiving the drugs. This study aimed to assess demographic characteristics and...
2.
Gottlieb H, Seghers L, Leiva-Fernandez F, Ghiciuc C, Hafez G, Herdeiro M, et al.
BMC Med Educ
. 2025 Mar;
25(1):339.
PMID: 40045247
Aim: Many patients are not taking their medicines. It has substantial negative medical and economic consequences for patients and healthcare systems but there is limited knowledge on how medication adherence...
3.
Windfuhr F, de Vries S, Melinder M, Dahlqvist T, Almeida D, Sepodes B, et al.
Drug Saf
. 2025 Feb;
PMID: 39987538
Background: The use of patient registries in regulatory, health technology assessment (HTA), and payer decision-making has gained increasing attention in recent years. Stakeholders' perspectives toward the use of registry-based real-world...
4.
Paraskevopoulos A, Wettermark B, Tsiligianni I
Drugs Aging
. 2025 Feb;
PMID: 39984778
Introduction: Polypharmacy is increasing among older individuals worldwide. Deprescribing has been suggested as a strategy to reduce polypharmacy, but it has had a limited impact. Objective: This study investigated the...
5.
Hallberg A, Aakjaer M, Aaltonen K, Andersen M, Pedersen E, Hajiebrahimi M, et al.
Arch Public Health
. 2025 Feb;
83(1):46.
PMID: 39980066
Background: During the initial phase of the COVID-19 pandemic, there was an intensive debate on which strategies would be most effective to minimize the negative societal impact of the pandemic....
6.
Hajiebrahimi M, Shihan H, Bratt O, Li H, Nyberg F, Wettermark B
Sci Rep
. 2025 Jan;
15(1):2648.
PMID: 39837931
The goal of this work is to investigate the sociodemographic characteristics and health status of women with breast cancer (BC) in association with COVID-19 by menopausal status. In a Swedish...
7.
Treciokiene I, Forslund T, Kahan T, Taxis K, Wettermark B
Pharmacoepidemiol Drug Saf
. 2025 Jan;
34(1):e70075.
PMID: 39777806
Purpose: Studies on antihypertensive treatment are important, as hypertension remains the major risk factor for cardiovascular morbidity and premature death. However, antihypertensive medicines are also used for other conditions, and...
8.
Samuelsen P, Wettermark B, Nyberg F, Hajiebrahimi M
Basic Clin Pharmacol Toxicol
. 2025 Jan;
136(2):e14119.
PMID: 39757371
The COVID-19 pandemic may have increased anticoagulant initiation due to the thrombogenic nature of the disease or decreased due to the societal impact of the pandemic. We aimed to study...
9.
Giunchi V, Fusaroli M, Linder E, Villen J, Raschi E, Lunghi C, et al.
Int J Pharm Pract
. 2024 Dec;
33(1):102-112.
PMID: 39740044
Human-use medicines are introduced into surface water throughout their entire life cycle, from manufacturing and consumption to improper disposal, resulting in negative effects on aquatic flora and fauna. Sustainability approaches...
10.
van Boven J, Dima A, Wettermark B, Potocnjak I, Agh T
Lancet Reg Health Eur
. 2024 Dec;
48:101164.
PMID: 39697213
No abstract available.